CCND1 and metastatic prostate carcinoma: Overexpression of cyclin D1 has been detected in numerous types of cancers, including cancers of the breast, lung and prostate [34–36] and has been considered as an oncogenic mechanism in hormone-refractory metastatic prostate cancer to the bone [36].